Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 75 of 3499 entries
View as:

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00022581 Org: User:
Start: 07/31/01 End: - Due: -

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00989651 Org: User:
Start: 10/28/09 End: 04/10/20 Due: 04/10/21

Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00040365 Org: User:
Start: 06/30/02 End: 06/30/11 Due: 06/30/12

Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00057863 Org: User:
Start: 01/31/03 End: 03/31/10 Due: 03/31/11

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05777603 Org: User:
Start: 04/18/24 End: 06/01/28 Due: 06/01/29

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02211755 Org: User:
Start: 10/06/14 End: 12/15/26 Due: 12/15/27

Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00019188 Org: User:
Start: 01/31/97 End: 03/31/07 Due: 03/31/08

CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT00016328 Org: User:
Start: 05/31/01 End: - Due: -

Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics

Phase: N/A Priority: Normal
NCT ID: NCT03027401 Org: User:
Start: 01/10/17 End: 10/05/20 Due: 10/05/21

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05112601 Org: User:
Start: 06/02/22 End: 04/30/26 Due: 04/30/27

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06287775 Org: User:
Start: 04/08/25 End: 07/25/29 Due: 07/25/30

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT06484062 Org: User:
Start: 09/16/25 End: 06/01/28 Due: 06/01/29

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03237780 Org: User:
Start: 07/20/18 End: 06/30/27 Due: 06/30/28

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05687123 Org: User:
Start: 08/14/24 End: 12/14/26 Due: 12/14/27

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05198830 Org: User:
Start: 12/15/22 End: 06/30/27 Due: 06/30/28

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02133196 Org: User:
Start: 10/23/14 End: 10/23/25 Due: 10/23/26

Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03030404 Org: User:
Start: 01/27/17 End: 03/31/25 Due: 03/31/26

Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00001499 Org: User:
Start: 03/31/96 End: 06/30/00 Due: 06/30/01

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03309878 Org: User:
Start: 10/24/18 End: 04/11/23 Due: 04/11/24

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05803382 Org: User:
Start: 11/08/23 End: 06/30/26 Due: 06/30/27

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03854474 Org: User:
Start: 11/18/19 End: 06/30/26 Due: 06/30/27

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04092270 Org: User:
Start: 05/07/20 End: 06/01/26 Due: 06/01/27

Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01445288 Org: User:
Start: 12/05/06 End: - Due: -

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Phase: N/A Priority: Normal
NCT ID: NCT03581292 Org: User:
Start: 11/06/18 End: 10/16/25 Due: 10/16/26

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT02496663 Org: User:
Start: 05/11/16 End: 06/30/27 Due: 06/30/28